MSD

R&D

This week in clinical trials: 2nd-5th January 2024

Despite the multiple challenges that faced clinical trials in 2023, according to GlobalData’s Pharmaceutical Intelligence Centre, some 22,338

News

Rumour mill says MSD is hunting Harpoon Therapeutics

MSD’s 2023 run of pipeline-building deals looks like it could continue into this year, with reports already emerging that the company is in talks to buy Harpoon Therapeuti

News

FDA holds back MSD’s chronic cough drug again

MSD will have to return to the drawing board to chart a course for US approval of its chronic cough treatment gefapixant.

News

Owkin and MSD join forces on AI-powered digital pathology

Pharma group MSD has joined forces with Owkin to develop artificial intelligence-powered digital pathology diagnostics that could be used to identify patients suitable for

News

MSD claims 2nd FDA approval for Welireg, in kidney cancer

The FDA has approved MSD’s oral HIF-2 alpha inhibitor Welireg for a second cancer indication, relapsed or refractory advanced renal cell carcinoma (RCC), the most common f

News